leadf
logo-loader
viewInnoCan Pharma

Innocan Pharma announces publication of two scientific articles supporting its CLX therapy for COVID-19-infected lungs

One article demonstrated the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms

InnoCan Pharma - Innocan Pharma Corporation announces publication of two scientific articles supporting its CBD-Loaded Exosomes (CLX) therapy for COVID-19-infected lungs
A product is planned to act as a 'guided missile' to the infected tissues, as the Exosomes migrate to Inflamed zones that are carrying CBD

Innocan Pharma Corporation (CSE:INNO) (FRA:IP4) announced Friday the recent publication of two scientific articles supporting its approach of using CBD-Loaded Exosomes (CLX) for the treatment of COVID-19.  

The company said the first paper entitled "Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients", was published in the Journal of Stem Cell Research & Therapy on October 15. It outlined that mesenchymal stem cells (MSCs) and their exosomes have potential therapeutic functions in the handling of COVID-19.

Specifically, Innocan said the study demonstrated that exosomes have the ability to enhance alveolar fluid clearance and promote epithelial and endothelial recovery through secretion of protective factors.

READ: Innocan Pharma's cosmetic clinical study indicates 90% wrinkle reduction in volunteers using SHIR Premium CBD Facial Serum

The second paper entitled "Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome" was published in the Journal of Cellular and Molecular Medicine on October 15.

It demonstrated that the non-psychoactive reagent in cannabis (CBD) can significantly reduce the lung damage induced by cytokine storms (which is a physiological reaction in humans and other animals in which the innate immune system causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines) caused by COVID-19.

The company said that Innocan Israel, a wholly-owned subsidiary, together with Tel Aviv University Professor Daniel Offen and his team, are developing a revolutionary combined therapy using MSC-driven Exosome-based loaded with CBD. The new combination is designed to target COVID-19 and neurodegenerative diseases.

Innocan said that through their potential synergistic anti-inflammatory effect, CBD-Loaded Exosomes hold the potential of helping the body fight against the COVID-19 virus's direct damage and its cytokine storm. This product is planned to act as a "guided missile" to the infected tissues, as the Exosomes migrate to Inflamed zones that are carrying CBD.

"The potential synergistic effect of CBD and Exosomes is of great potential for COVID-19 and other diseases known for local inflammation that causes destruction,” Offen said in a statement. “We are doing our best efforts to accelerate the development and to potentially offer a new approach for the COVID-19 treatment."

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: InnoCan Pharma

Price: 0.225 CAD

CSE:INNO
Market: CSE
Market Cap: $39.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Catenae Innovation focused on commercialising Cov-ID app after positive...

Catenae Innovation PLC's (LON:CTEA) Guy Meyer caught up with Proactive London's Andrew Scott after announcing its partner Newcastle Premier Health has successfully completed a proof-of-concept pilot trial of the Cov-ID app. Cov-ID is GDPR compliant identity documentation exchange system to...

on 19/6/20

2 min read